Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 23, 2023 16:01 ET | Source: Invivyd

Invivyd Reports Full Year 2022 Financial Results and Business Highlights

Advancing VYD222 into clinical development based on in vitro data demonstrating neutralizing activity against multiple important variants of concern, including XBB.1.5 Anticipate near-term...
March 22, 2023 16:30 ET | Source: Invivyd

Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19

Research published online today in peer-reviewed journal Science Translational MedicineAnalysis of data from a Phase 2/3 COVID-19 prevention study (EVADE) of adintrevimab suggests clinically...
March 16, 2023 07:00 ET | Source: Invivyd

Invivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business Highlights

WALTHAM, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
March 06, 2023 07:00 ET | Source: Invivyd

Invivyd Optimizes Development Efficiency with Election of VYD222 for Near-Term Clinical Advancement to Address Urgent Unmet Need for COVID-19 Monoclonal Antibodies

Company seeks to utilize emerging global COVID-19 regulatory frameworks to accelerate development of VYD222 and its pipeline of other candidates VYD222 mAb candidate has demonstrated in vitro...
February 28, 2023 07:00 ET | Source: Invivyd

Invivyd to Participate at Cowen’s 43rd Annual Healthcare Conference

WALTHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory...
February 03, 2023 07:30 ET | Source: Invivyd

Invivyd Announces Changes to Executive Team

WALTHAM, Mass., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical stage biopharmaceutical company on a mission to protect humanity from serious infectious diseases, today...
December 19, 2022 07:00 ET | Source: Invivyd

Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop

WALTHAM, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases,...
December 06, 2022 16:01 ET | Source: Invivyd

Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer

WALTHAM, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases,...
November 17, 2022 07:00 ET | Source: Invivyd

Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19

-Broad partnership will strengthen Invivyd’s development platform and organizational capabilities towards acceleration of NVD200 clinical program and future engineered antibodies for COVID-19 and...
November 10, 2022 16:01 ET | Source: Invivyd

Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights

Novel monoclonal antibody combination candidate (NVD200) on track to advance into clinical trials in Q1 2023 $419 million in cash, cash equivalents and marketable securities expected to support...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right